Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Editorial from The New England Journal of Medicine — Cardioprotection with Yet Another SGLT2 Inhibitor — An Embarrassment of Riches

  • 123456 Profile photo of Madelyn

    Evidence for the cardiovascular benefits of sodium–glucose cotransporter 2 (SGLT2) inhibitors continues to accumulate. Most recently, Bhatt et al. performed two randomized trials to investigate the cardiovascular effects of sotagliflozin; their findings are now reported in the Journal.1,2 Sotagliflozin, unlike other drugs in this class, also has an inhibitory effect on intestinal SGLT1, a related sodium–glucose cotransporter. The first trial, Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF),1 involving 1222 participants with type 2 diabetes who had a very recent episode of decompensated heart failure, was designed to determine the efficacy and safety of sotagliflozin in preventing